Education
About Us
Working with TipRanks
Follow Us
Biora Therapeutics Inc. (BIORQ)
:BIORQ
Top Page
Biora Therapeutics
(OTC:BIORQ)
Rating:7Underperform
Price Target:―
Positive Factors
Clinical Trials
Positive results from the BT-600 Phase 1 clinical trial were presented at a major gastroenterology conference, highlighting potential advances in treatment.
Product Development
The new smaller BioJet device increases payload capacity and ease of administration, potentially expanding its applications and market interest.
Product Safety and Efficacy
The NaviCap device is developing as a safe and effective means to deliver medication directly to the colon, with minimal systemic exposure.
Strategic Alignment
Biora's strategic realignment to focus on the BioJet program aims to expedite results crucial for licensing and partnering discussions with major pharmaceutical companies.
Negative Factors
Financial Performance
Biora reported a third-quarter EPS of ($5.04), missing both the estimate of ($4.20) and the consensus estimate of ($3.85).
Biora Therapeutics (BIORQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$520.11K
Dividend YieldN/A
Average Volume (3M)9.75K
Price to Earnings (P/E)―
Beta (1Y)1.49
Revenue Growth4855.56%
EPS Growth88.66%
CountryUS
Employees58
SectorHealthcare
Sector Strength39
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,522,702
10 Day Avg. Volume3,010
30 Day Avg. Volume9,751
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap105.31
Enterprise Value/Revenue31.05
Enterprise Value/Gross Profit38.25
Enterprise Value/Ebitda-2.28
Forecast
1Y Price Target
$23.00Price Target Upside19066.67% Upside
Rating ConsensusHold
Number of Analyst Covering0
Biora Therapeutics Business Overview & Revenue Model
Company DescriptionProgenity Inc is a biotechnology company. It is engaged in developing and commercializing molecular testing products. The company is translating innovation into precision medicine through diagnostic and therapeutic development platforms based on genomics, proteomics, and microbiomics. The firm generates its revenue from molecular laboratory tests, principally from the sale of Innatal, Preparent, and pathology molecular testing.
How the Company Makes MoneyBiora Therapeutics makes money primarily through the development and commercialization of its proprietary drug delivery platforms and therapeutics. The company generates revenue by partnering with other pharmaceutical companies to co-develop products, licensing its technology, and through direct sales of its therapeutics. Significant factors contributing to its earnings include successful clinical trials, regulatory approvals, and strategic partnerships that expand its market reach and enhance distribution capabilities.
Biora Therapeutics Earnings Call Summary
Earnings Call Date:May 07, 2025
(Q2-2024)
| % Change Since: -14.29%|
Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant advancements in clinical trials and partnerships, especially for the NaviCap and BioJet platforms, alongside strong financial backing from investors. However, the company faces operational challenges with legacy costs and high operating expenses.Q2-2024 Updates
Positive Updates
Successful Phase I Clinical Trial for BT-600
The NaviCap platform demonstrated successful delivery of tofacitinib directly to colon tissue in ulcerative colitis patients, achieving a PK profile consistent with colon drug delivery and significantly lower systemic levels, potentially reducing toxicity risks.
Progress in BioJet Platform Partnerships
Active partnership discussions with multiple large pharma companies for the BioJet platform, with anticipated completion of at least one partnership in the near term, highlighting industry interest in the technology.
Strong Financial Support
Secured an additional $16 million in capital from existing investors, structured to provide funding in $4 million increments as needed, ensuring financial stability while pursuing partnerships.
BioJet Platform Performance
BioJet platform demonstrated high bioavailability of approximately 40% for large molecules, comparable to subcutaneous injection standards, promising a non-invasive alternative to needle-based delivery systems.
Negative Updates
Legacy G&A Costs
Approximately 40% of G&A costs are associated with legacy matters, which the company aims to eliminate by the end of the year, indicating ongoing financial inefficiencies.
High Operating Expenses
Operating expenses for the quarter totaled $14.5 million (excluding stock-based compensation), with significant allocation towards R&D and preclinical activities.
Company Guidance
During the Biora Therapeutics Q2 2024 earnings call, the company provided guidance on several key metrics and future plans. The focus was on the successful Phase I clinical trial for the BT-600 program using the NaviCap platform, targeting ulcerative colitis, which demonstrated promising pharmacokinetic (PK) profiles and tissue drug exposure. The company reported significant lower systemic drug levels, 3 to 4 times lower than traditional oral delivery, potentially reducing toxicity risks. Biora also announced active partnership discussions for the BioJet platform, aimed at improving the oral delivery of large molecules, with a goal to finalize at least one partnership in 2024. Financially, the company reported operating expenses of $14.5 million for the quarter, excluding stock-based compensation, and a core OpEx of $11.7 million. They have secured an additional $16 million funding from investors, structured as a bridge to anticipated pharma partnerships.Biora Therapeutics Financial Statement Overview
Summary
Biora Therapeutics is facing significant financial challenges, with declining revenue, persistent losses, high leverage, and negative cash flows, indicating financial instability and potential distress.Income Statement
Biora Therapeutics has shown a significant decline in revenue over the past years, with the latest TTM revenue at $1.76 million compared to $143.99 million in 2019. Gross profit margins are positive in TTM but have fluctuated, suggesting instability in cost management. The company has consistently reported negative EBIT and net income, indicating ongoing operational challenges and lack of profitability.12
Very Negative
Balance Sheet
The balance sheet reveals a highly leveraged position with negative stockholders' equity, reflecting financial distress. The company's debt-to-equity ratio is not meaningful due to negative equity. Total liabilities significantly exceed total assets, raising concerns about solvency. The lack of equity cushion and substantial liabilities pose financial risks.8
Very Negative
Cash Flow
Operating cash flows are consistently negative, indicating cash burn from operations. Despite occasional positive financing cash flows, free cash flow remains negative, highlighting liquidity pressures. The company struggles to convert net income into cash, as evidenced by negative free cash flow to net income ratios.10
Very Negative
| Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.76M | 4.00K | 305.00K | 1.25M | 74.31M | 143.99M |
| Gross Profit | 1.43M | 4.00K | -602.00K | -190.00K | -19.12M | 43.49M |
| EBITDA | -24.06M | -114.05M | -37.35M | -164.57M | -106.18M | -135.44M |
| Net Income | -31.54M | -124.11M | -48.83M | -178.52M | -192.53M | -148.04M |
Balance Sheet | ||||||
| Total Assets | 14.51M | 31.21M | 53.52M | 108.84M | 154.44M | 101.73M |
| Cash, Cash Equivalents and Short-Term Investments | 3.20M | 15.21M | 30.49M | 88.40M | 92.08M | 33.04M |
| Total Debt | 39.65M | 47.43M | 127.81M | 126.40M | 162.31M | 73.37M |
| Total Liabilities | 121.13M | 132.64M | 155.81M | 193.81M | 261.43M | 185.60M |
| Stockholders Equity | -106.63M | -101.42M | -102.29M | -84.98M | -106.99M | -83.87M |
Cash Flow | ||||||
| Free Cash Flow | -5.50M | -48.60M | -65.21M | -168.34M | -170.69M | -109.85M |
| Operating Cash Flow | -5.37M | -48.50M | -64.42M | -167.49M | -165.74M | -106.12M |
| Investing Cash Flow | 7.84M | 2.44M | -792.00K | -1.24M | -4.94M | 16.52M |
| Financing Cash Flow | 31.27M | 30.78M | 7.30M | 165.05M | 229.72M | 73.64M |
Biora Therapeutics Technical Analysis
Negative
0.12
Price Trends
0.17
Negative
0.16
Negative
0.73
Negative
Market Momentum
-0.01
Positive
35.33
Neutral
3.76
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIORQ, the sentiment is Negative. The current price of 0.12 is below the 20-day moving average (MA) of 0.21, below the 50-day MA of 0.17, and below the 200-day MA of 0.73, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 35.33 is Neutral, neither overbought nor oversold. The STOCH value of 3.76 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIORQ.
Biora Therapeutics Risk Analysis
Biora Therapeutics disclosed 68 risk factors in its most recent earnings report. Biora Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Biora Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$17.46B | 5.12 | -4.88% | 3.74% | 9.34% | -38.39% | |
45 Neutral | $3.30M | ― | -468.00% | ― | ― | 98.55% | |
30 Underperform | $1.34M | ― | -300.16% | ― | ― | 79.57% | |
29 Underperform | $1.30M | ― | -91.39% | ― | ― | 99.39% | |
29 Underperform | $8.52M | ― | -192.72% | ― | ― | 56.26% | |
7 Underperform | $520.11K | ― | 29.58% | ― | 4855.56% | 88.66% | |
| ― | $1.97M | ― | -33.24% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
BIORQ
Biora Therapeutics
0.12
-5.77
-97.96%
SLRX
Salarius Pharmaceuticals
0.58
-1.48
-71.84%
ENTO
Entero Therapeutics
0.41
0.17
70.83%
PCSA
Processa Pharmaceuticals
0.24
-1.43
-85.63%
GRI
GRI Bio
1.29
-7.38
-85.12%
ZVSA
ZyVersa Therapeutics
0.18
-2.83
-94.02%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.